Clinical trial
A Phase Ⅲ, Multicenter, Prospective, Open-Label, Controlled Study of Supermicrosurgical Lymphaticovenous Anastomosis for Prevention of Upper Limb Lymphedema in Breast Cancer Patients Following Axillary Lymph Node Dissection and Adjuvant Radiotherapy
NCT07026292 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅲ, Multicenter, Prospective, Open-Label, Controlled Study of Supermicrosurgical Lymphaticovenous Anastomosis for Prevention of Upper Limb Lymphedema in Breast Cancer Patients Following Axillary Lymph Node Dissection and Adjuvant Radiotherapy
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- July 1, 2025
- Completion date
- May 31, 2029
- Enrollment
- 120 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer invasive, breast cancer-related lymphedema, lymphedema